Ambu A/S
The answer first
Does Ambu beat the market?
No, Ambu has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 71% of Nordic stocks
- Quality82
- Value23
- Trend79
No. 36 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Ambu keeps must grow about 14% a year for 10 years.
Max for seven days
Follow Ambu with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Ambu
Your first answer is free, no account needed.
Do you own Ambu, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Ambu and a few more. Free, no card.
Super Stock+45.9%In short
- Ambu has risen 5.9% over the past year, including dividends.
- Overall, Ambu ranks better than 71% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 78.0%. The price is 74.6% below its peak now.
Who owns Ambu? See the major shareholders and their stakes
What do analysts think of Ambu?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 71% of Nordic stocks.
No. 36 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 46 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.11
- Asset turnoverSales divided by everything the company owns0.79
- Return on equityProfit divided by equity+10.3%
- Cash conversionOperating cash flow divided by profit1.66
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 90 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity3.6
- P/SPrice divided by sales3.5
- P/EPrice divided by earnings35.4
- P/CFPrice divided by operating cash flow21.4
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 40 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+18.2%
- 6 months+32.3%
- 9 months+9.3%
- 12 months+5.9%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Ambu
17 funds we follow own Ambu. The share is how much of the fund the stock makes up.
- Norway3
- Sweden7
- Denmark7
- 1 ETF
- SEB Europafond SmåbolagSweden · SEB1.8%
- Case All StarSweden · Case1.6%
- BIX Danske Aktier Indeks ADenmark · BIX0.7%
- BIX Danske Aktier Indeks Akk ADenmark · BIX0.7%
- Danske Invest Danmark IndeksDenmark · Danske Invest0.7%
- Sparindex INDEX OMX C25 KLDenmark · Sparindex0.7%
- Sparinvest INDEX OMX C25 KLDenmark · Sparinvest0.7%
- Xact KapitalforvaltningDenmark · XACT · ETF0.6%
Show all 17
- Nordnet Indeksfond Danmark ASweden · Nordnet0.6%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.5%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg0.1%
- DNB Norden Indeks ANorway · DNB0.1%
- KLP AksjeNorden IndeksNorway · KLP0.1%
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo0.1%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
From the funds' latest known holdings.
About Ambu
Ambu A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 4,700 employees.
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes.


See the full analysis of Ambu.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card